• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    QuidelOrtho Announces New R&D Executive Leader

    10/9/24 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QDEL alert in real time by email

    Jonathan Siegrist appointed as EVP of R&D and CTO

    QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009251239/en/

    Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire)

    Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire)

    Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedical engineering. He most recently was the CTO and Head of Assay Research and Development at Cepheid. Prior to Cepheid, he co-founded a diagnostics manufacturing company.

    Reporting to Brian Blaser, President and Chief Executive Officer, Siegrist will spearhead QuidelOrtho's R&D strategy with a focus on menu expansion and advancing critical platforms. His leadership is expected to advance QuidelOrtho's industry-leading expertise in immunoassay and molecular testing and award-winning solutions in clinical labs and transfusion medicine. Werner Kroll, Senior Vice President, R&D, will support a smooth leadership transition and related activities until his retirement in March 2025.

    "QuidelOrtho is at a pivotal point in our history, and Jonathan's deep industry knowledge and insights in assay R&D and proven leadership make him an excellent fit for this role. We are confident his innovative approach will help us navigate our current opportunities and lead the company to success," said Brian Blaser, President and Chief Executive Officer, QuidelOrtho.

    Siegrist holds a PhD and Master of Science from the University of California, Irvine, and a Bachelor of Science in Electrical Engineering from the University of California, Los Angeles. His career has been marked by successful leadership roles across multiple disciplines within R&D.

    QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit www.quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook, and X.

    About QuidelOrtho Corporation

    QuidelOrtho Corporation (NASDAQ:QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

    Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

    Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.

    Source: QuidelOrtho Corporation

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241009251239/en/

    Get the next $QDEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QDEL

    DatePrice TargetRatingAnalyst
    5/8/2025$44.00Hold → Buy
    Jefferies
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    12/10/2024$43.00Hold
    Jefferies
    9/19/2024$42.00 → $50.00Neutral
    UBS
    9/5/2024$40.00 → $57.00Hold → Buy
    Craig Hallum
    3/4/2024$70.00 → $42.00Neutral → Sell
    UBS
    2/14/2024$66.00 → $37.00Neutral → Underweight
    JP Morgan
    12/11/2023$95.00 → $72.00Buy → Neutral
    Citigroup
    More analyst ratings

    $QDEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • QuidelOrtho Reports First Quarter 2025 Financial Results

      ― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on cost-savings initiatives driving improved margins and profitability ― ― Company maintains full-year 2025 financial guidance ― First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency Labs revenue grew 5% as reported and 7% in constant currency Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of

      5/7/25 4:05:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho to Report First Quarter 2025 Financial Results

      QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company") or ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.c

      4/23/25 4:30:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho® Introduces Results Manager™ System

      Elevating laboratory efficiency and patient care QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho") announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address the growing demands of modern laboratories. The Results Manager system provides a seamless, user-friendly experience for community hospitals and point-of-care settings, strengthening informatics capabilities across QuidelOrtho's extensive diagnostics portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310329666/en/QuidelOrtho® Results Manager™ System (Graphic: Business Wire) The QuidelOrtho Results Manage

      3/10/25 9:00:00 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

      SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      12/6/24 10:11:24 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

      SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

      11/21/24 5:10:19 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

      SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      11/14/24 1:28:35 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Financials

    Live finance-specific insights

    See more
    • QuidelOrtho Reports First Quarter 2025 Financial Results

      ― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on cost-savings initiatives driving improved margins and profitability ― ― Company maintains full-year 2025 financial guidance ― First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency Labs revenue grew 5% as reported and 7% in constant currency Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of

      5/7/25 4:05:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho to Report First Quarter 2025 Financial Results

      QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company") or ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.c

      4/23/25 4:30:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results

      Strong finish to 2024 with continued progress in cost-savings initiatives to drive adjusted EBITDA margin expansion in 2025 and beyond Company issues full-year 2025 financial guidance Fourth Quarter and Full-Year 2024 Results (all comparisons are to the prior year period) Fourth quarter 2024 revenue was $708 million, as reported Non-respiratory revenue was $565 million, which was flat compared to the prior year period due to a decline in U.S. Donor Screening revenue, a business the Company is exiting; Labs revenue grew 4%, as reported and in constant currency, excluding COVID-19 and non-core revenues1 Respiratory revenue was $143 million, a decrease of 18%, as reported and in co

      2/12/25 4:05:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operations Officer Mclellan Philip D. was granted 1,945 shares and covered exercise/tax liability with 696 shares, increasing direct ownership by 14% to 10,237 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      4/29/25 4:09:19 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Operations Officer Mclellan Philip D. covered exercise/tax liability with 1,159 shares and was granted 3,237 shares, increasing direct ownership by 30% to 8,988 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      4/24/25 4:03:44 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Hodges Michelle A

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      4/22/25 4:03:40 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    SEC Filings

    See more
    • QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - QuidelOrtho Corp (0001906324) (Filer)

      5/7/25 4:07:42 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEFA14A filed by QuidelOrtho Corporation

      DEFA14A - QuidelOrtho Corp (0001906324) (Filer)

      4/8/25 4:06:30 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEF 14A filed by QuidelOrtho Corporation

      DEF 14A - QuidelOrtho Corp (0001906324) (Filer)

      4/8/25 4:05:50 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • QuidelOrtho upgraded by Jefferies with a new price target

      Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

      5/8/25 9:44:58 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho upgraded by Citigroup with a new price target

      Citigroup upgraded QuidelOrtho from Neutral to Buy and set a new price target of $50.00 from $44.00 previously

      12/11/24 8:21:07 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Jefferies initiated coverage on QuidelOrtho with a new price target

      Jefferies initiated coverage of QuidelOrtho with a rating of Hold and set a new price target of $43.00

      12/10/24 8:01:07 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Blaser Brian J. bought $249,878 worth of shares (6,033 units at $41.42) (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      12/13/24 4:12:57 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Busky Joseph M bought $99,663 worth of shares (2,150 units at $46.35) (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      2/26/24 6:48:23 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • QuidelOrtho Announces New R&D Executive Leader

      Jonathan Siegrist appointed as EVP of R&D and CTO QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009251239/en/Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire) Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedi

      10/9/24 7:00:00 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer

      QuidelOrtho Corporation (NASDAQ:QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho's human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910545042/en/Lee Bowman, Chief Human Resources Officer, QuidelOrtho (Photo: Business Wire) Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key roles in major industries.

      9/10/24 7:00:00 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care